21,850 Shares in Omeros Co. (NASDAQ:OMER) Bought by Cerity Partners LLC

Cerity Partners LLC acquired a new position in shares of Omeros Co. (NASDAQ:OMER) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 21,850 shares of the biopharmaceutical company’s stock, valued at approximately $71,000.

A number of other institutional investors also recently bought and sold shares of OMER. SG Americas Securities LLC purchased a new position in shares of Omeros during the third quarter worth about $56,000. Barclays PLC grew its stake in shares of Omeros by 51.2% in the 3rd quarter. Barclays PLC now owns 45,629 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 15,456 shares during the last quarter. Finally, Ancora Advisors LLC grew its stake in shares of Omeros by 23.1% in the 3rd quarter. Ancora Advisors LLC now owns 210,023 shares of the biopharmaceutical company’s stock valued at $613,000 after purchasing an additional 39,475 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Stock Performance

OMER stock opened at $3.15 on Wednesday. Omeros Co. has a one year low of $0.92 and a one year high of $7.80. The company has a fifty day moving average of $3.69 and a 200-day moving average of $3.04. The stock has a market capitalization of $182.51 million, a PE ratio of -1.68 and a beta of 1.34.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Monday, April 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter. Equities analysts forecast that Omeros Co. will post -1.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, April 3rd.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.